Bisphosphonates: Are they standard of care for the treatment of breast cancer?

British Journal of Cancer

Volumn 96, Issue 12, 2007, Pages 1781-1782

  Pritchard, K I ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PLACEBO; RISEDRONIC ACID;

ADJUVANT THERAPY; BONE METASTASIS; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; OSTEOPOROSIS; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CLODRONIC ACID; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 34250364802     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603836     Document Type: Editorial

References (19)

1. American Dental Association (2006) Report of the council of scientific affairs. Expert panel recommendations: dental management of patients on oral bisphosphonate therapy. J Am Dental Assoc 137: 1144-1150
2. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580-8587
3. Bilezikian J (2006) Osteonecrosis of the jaw - do bisphosphonates pose a risk? N Engl J Med 355: 2278-2281
4. Brown JP, Josse RG, for the Scientific Advisory Council of the Osteoporosis Society of Canada (2002) 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167: S1-S34
5. Conte PF, Guarneri V (2005) In response to body letter to the editor regarding safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 10: 318-319
6. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM (1996) Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group 372. J Clin Oncol 14: 2552-2559
7. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New Engl J Med 339: 357-363
8. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee G, Janjan N, Cauley JA, Blumenstien BA, Albain K, Lipton A, Brown S (2003) ASCO 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21: 4042-4057
9. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group 277. New Engl J Med 335: 1785-1791
10. Hortobagyi GN, Theriault R, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M, Mellars K, Reitsma DJ (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16: 2038-2044
11. Lipton A, Hershey PA, Theriault R, Leff R, Gluck S, Waratah JS (1997) Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy by monthly 90 mg Pamidronate infusions. Proc Am Soc Clin Oncol 16: 531
12. Mavrokokki T, Cheng A, Stein B, Goss A (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65: 415-423
13. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer (ISRCTN83688026). Breast Cancer Res 8: R13
14. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Mannisto E, Suovuori A, Atula S, Nevalainen J, Pylkkanen L (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20: 3219-3224
15. Ruggiero S, Mebrotra B, Rosenberg T, Engroff S (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62: 527-534
16. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C (2004) Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43: 650-656
17. Saarto T, Blomqvist C, Virkkunen P, Elomaa I (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19: 10-17
18. Wendler D, Shalowitz D (2006) Bisphosphonates and osteonecrosis of the jaw. Ann Intern Med 145: 791-792
19. Woo SB, Hellstein JW, Kalmar JR (2006) Systemic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144: 753-761